HJURP and lung carcinoma: At the optimal cut-off point, plasma HJURP separated lung cancer patients from healthy individuals with a sensitivity of 66.0%, a specificity of 78.6%, and an AUC (area under the ROC) of 0.696 (Zhou et al., 2017).